Pharvaris to Participate in BioCapital Europe

Rhea-AI Summary

Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on oral bradykinin-B2-receptor antagonists for hereditary angioedema (HAE), announced CEO Berndt Modig's participation in BioCapital Europe. The event will feature a panel presentation titled “Shaping the New Biotech Reality – Key Lessons from COVID” on March 10, 2021, at 18:30 CET. Additionally, a corporate presentation will occur on March 11, 2021, at 14:50 CET. Both presentations will be accessible for 30 days on the Pharvaris website.

ZUG, Switzerland, March 04, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that Berndt Modig, chief executive officer and co-founder of Pharvaris, will participate in BioCapital Europe, to be held virtually on March 11, 2021.

Participation Details:
Title: “Shaping the New Biotech Reality – Key Lessons from COVID” Panel Presentation
Date/Time: March 10, 2021, 18:30 CET (12:30 p.m. EST)

Title: Pharvaris Corporate Presentation
Date/Time: March 11, 2021, 14:50 CET (8:50 a.m. EST)

The virtual presentation will be available for 30 days on the Pharvaris website at https://ir.pharvaris.com/news-events/events-presentations.

About Pharvaris
Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. For more information, visit https://pharvaris.com/.

Investor Contact
Chad Rubin, Solebury Trout
crubin@soleburytrout.com

Media Contact
Maggie Beller, Russo Partners, LLC
maggie.beller@russopartnersllc.com
+1-646-942-5631

FAQ

What is Pharvaris's participation in BioCapital Europe on March 11, 2021?

Pharvaris will participate in BioCapital Europe with a corporate presentation scheduled for March 11, 2021, at 14:50 CET.

Who is the CEO of Pharvaris and what event is he speaking at?

CEO Berndt Modig will speak at BioCapital Europe, participating in a panel presentation on March 10, 2021.

Where can I watch Pharvaris's presentations from BioCapital Europe?

The presentations will be available for 30 days on the Pharvaris website after the event.

What topics will Berndt Modig discuss at BioCapital Europe?

He will discuss key lessons from COVID-19 in the panel presentation titled 'Shaping the New Biotech Reality.'